Member Info for Silverfoil13

Thank you Bojo
I think the Directors know there is a risk return balance between the return of cashing in earlier or later v the risk of hanging on too long and trial results going against SAR. Nothing is a dead cert in this game.
I would be very happy with a takeover at or above the 28p if it came relatively soon (next 6-12 months) even it meant missing out on 50p plus in 2023 or later. I’m 67 and want a bit of time to enjoy the return from SAR and the Directors are a similar age to me and part of their thought process might be similar to mine .. who knows!!

We have 4 key products all targeting different types of cancer all producing strong positive results so far at each stage of trialling.
CHK1/SRA737 (targeting ovarian, anogenital and prostrate cancers among others) is the most advanced after successful human trials in 19/20. Licence deal already in place with Sierra worth up to 300 million. Stalled in Summer 2019 when Sierra prioritised other product development but now in play again with Sierra planning trials in combo with AZD WEE1 in mid 2022. So no more news likely now till late 2022.
TYK2/JAK1 1801 (targeting autoimmune diseases like psoriasis, rheumatoid arthritis inflammatory bowel diseases) best in class strong pre clinical results including tumour regression in mice 10/10, with US military/SRI results in mice inhibiting cytokines re Lupus, shown to be superior to Dexamethasone plus potential to treat COVID. Human clinical trials delayed from 2020 to 2021 now to 2022. So frustrating delays in progress here.
TYK2/JAK1 1802 (targeting lymphoma and leukaemia) fully patented but again human clinical trials delayed from 2020 to 2021 and now to 2022 so again frustrating delays.
FLT3 Aurora (targeting leukaemia and other blood cancers) licensed to a Chinese company in 2020 but taken back in 2021. Seeking new partner so stalled.
So it seems to me it will be next year before we see any positive advance on the scientific front.
Looking at price drivers over last 18 months.
Mid late 2020 saw price move from 0.4p to 2.5p because of positive 1801 results (mice/SRI and cytokines), US patent applications 1802, Nature article showing potential for 1801 v Covid, UKRI grant.
2021 price driven up to 9p by HNWI investment, Sierra taking up the 737 baton again in combo with AZD WEE1, great test results for 1801 v Covid and US patent grant for 1802.
It seems to me likely price drivers before the human trials planned in 2022 would be
A license deal on 1801 or 1802
A new deal re FKT3 Aurora
News about what the Secret Patent is all about
Agile funding
Further HNWI interest
Takeover
Just my simple analysis of where I think we have been and where we are going. More learned posters than me will be able to correct my interpretation and add more insight.

So basically SDC1801 v sepsis.
SAR need to update their website because they are still saying human clinical trials in 2021 for 1801 but in the Accounts and investor presentation they were saying mid 2022.
A couple of months ago one of the Directors tweeted simply “into the lab”; any ideas what that was for?

Thoth2 has often mentioned sepsis as a potential target for SAR products with huge potential. Just wondered which one of our 4 key products is the one aimed at this?

Wouldn’t have thought a blue day was likely at 10.30 but looks a possibility now! In the absence of rumours or news just shows the short term havoc the pen twiddlers can wreak!
Obviously the best thing to do is look away for a few days or weeks but easier said then done when you are looking at such a potentially beautiful story as this not just for us as shareholders but also on a human level for all the people who will potentially benefit health wise from SAR’s brilliant science

Takeover talk is inevitable and exciting; I would think that for many here 15-25p would see them well pleased and sorted. Anything above that would be a once in a lifetime bonus.

Fireworks .. I know it’s my daughters birthday!!

Hopefully they got some good tax advice when they set SAR up in 2003 (possibly EIS relief) which should help minimise any tax liabilities.

I would expect a broker update with a target from PH quite soon.
Just looked up “broker targets” and found

“Broker recommendations and price targets are projections of a company’s share price performance across a given period of time. Typically updated following the most recent trading update or financial report, they provide an insight into the sentiment shared amongst industry professionals towards a particular company”

Sounds like one of the things you would expect from your broker then!

Deferring salary is not something I ever saw at RKH sadly the worst investment I ever made even though oil in the Falklands was (and still is) a good story. At RKH they just kept taking till there was virtually nothing left.
I think we are dealing with different philosophies here.

I seem to recall the Directors had foregone some of their salaries at some point quite recently. If my recollection is correct then you can hardly blame them for selling a few shares .. everybody needs to live. Nothing changes the science or long term prospects which the guys were clearly very excited about in yesterday’s presentation.
However a complete pain in the butt for anyone looking for say 9-12p in the next few weeks.

Surely at some point our new broker PH will issue a price target for SAR as brokers usually do? That will be interesting!!

Indeed .. Avis up 1000% in a year .. now that would be nice!!

Finally got a few questions in but not included in answers during webinar probably because too sensitive. I asked how the age profile of the senior executives might affect the development of products and the company and where SAR saw itself in 3 years time. Probably unlikely to get responses but worth trying!

SAR are conscious of striking a balance between risk and return of early v late stage deals, plan to out licence products before products go to market, would consider any transaction where terms would be beneficial to SAR, do not believe entry into AGILE would mean loss of control over the program? PH provides extra routes into institutional investors.
All seems to suggest an earlier rather than a later deal is likely.

Frustrating keep clicking on the QandA link on the webinar screen but takes me nowhere so can’t ask a question?!!

Tim said early on that the deal with Sierra on SRA737 was worth $300 million. Is that a figure that has been discussed before? How is that calculated?

I totally agree MrD re the age of the team at SAR being an important consideration. I sold my business in November last year aged 66 because I could sense I was just gradually running out of steam and losing a bit of the enthusiasm and drive and these guys may be start to feel the same at some point and want to cash in .. so they still have time to enjoy the fruits of their brilliant work. Quite a few on here should also enjoy the benefits of the SAR team’s amazing work!!

Bit of fun courtesy of SCH while we wait patiently for tomorrow and beyond. How about Takeda? I had a fantastic ride with Shire Pharmaceutricals between 2003 and 2019 before they were taken over by Takeda in 2019. Be happy to enjoy similar success from SAR from here!

On LSE since 10 AM 56 buys and 6 sells but price down until a few minutes ago .. bazaar!!